Page URL:

New DMD treatment shows promise in early trials

7 January 2008
Appeared in BioNews 439

An experimental treatment for boys with the inherited muscle wasting disease Duchene Muscular Dystrophy (DMD) has showed promise in human safety trials, according to a study published in the New England Journal of Medicine. In the first ever trial on humans, the new drug was shown to help DMD patients produce dystrophin - an essential muscle protein missing in DMD patients.

DMD is a muscle-wasting disease that causes a steady deterioration of muscles and often results in death before the age of 30. The condition, which is usually inherited and incurable, affects one in 3500 male newborn boys and is caused by a fault in the gene that encodes the body's instructions for making dystrophin.

The treatment, developed by the Dutch pharmaceutical company Prosensa, uses an 'antisense-RNA' - a chemical relative of DNA - as a 'molecular patch' to fix the genetic defect which causes DMD. In the trial, four DMD boys aged 10-13 received an injection of the drug - called PRO051 - into a leg muscle and four weeks later low levels of dystrophin were measured in all four boys.

Although not enough dystrophin was produced to reduce the symptoms of DMD in the boys, the researchers have taken the results as 'proof of principal' - an indication the treatment is safe and could potentially be effective if administered in larger doses throughout the body.

Prof Gert-Jan van Ommen, together with his colleagues Dr Judith van Deutekom and Dr Jan Verschuuren, responsible for the research, reported that the next step would be to carry out a 'systemic' trial where the drug was injected under the skin of the patients, delivering the drug to muscles all over the body. 'The robust expression in all four patients with different mutations after a single injection points to a solid effect. The results form an excellent starting point for systemic treatment trials', they said in a statement.

DMD is caused by a variety of different mutations and so the PRO051 drug will only be suitable for around 13 per cent of all DMD patients explained Prof van Ommen. This means that if the technique works, it would probably take 10 different antisense drugs to treat about half of all children with Duchenne's, he said. Experts have warned that, if effective, the drug will be expensive - costing perhaps more than £100,000 - and will need to be administered throughout the patient's life to be effective.

Gene-based approach to muscular dystrophy tested |  2008
In treating muscular dystrophy, an early drug test shows promise
International Herald Tribune |  2 January 2008
Leiden University Medical Center and Prosensa B.V. Announce New England Journal of Medicine Publication of First Successful Clinical Study with RNA-based Therapeutic PRO051 in Duchenne Muscular Dystrophy
Leiden University |  27 December 2007
Science: Boffin log
The Daily Telegraph |  2008
15 November 2009 - by Alison Cranage 
Research published in the journal Science Translational Medicine last week shows gene therapy can improve muscle size and strength in monkeys. The technique holds promise as a therapy for several neuromuscular disorders, and researchers hope that clinical trials will start next year....
9 March 2009 - by Rosie Beauchamp 
It was reported this week in the journal Stem Cell that a group of researchers from the University of New South Wales, Australia, have made a major breakthrough in the success of regrowing damaged muscle tissue using adult stem cells. Previous research carried out at the University...
27 January 2008 - by Dr Rebecca Robey 
Researchers at the University of Texas Southwestern Medical Centre have developed a new technique to treat the symptoms of muscular dystrophy using embryonic stem (ES) cells. The group, reporting in the February 2008 issue of Nature Medicine, successfully manipulated mouse ES cells to transform them into muscle-forming...
17 December 2007 - by Ailsa Stevens 
Adult stem cells harvested from human patients with the muscle wasting disease Duchene Muscular Dystrophy (DMD) can be genetically corrected and used to improve muscle strength in mice with DMD, according to a study published in the journal Cell Stem Cell last week. The researchers, based at...
24 September 2007 - by Ailsa Stevens 
The first trial of a new treatment for Duchenne muscular dystrophy (DMD) will start later this year in the UK. The treatment, which has been developed by using human cells and mice experiments, hopes to overcome the effects of the genetic defect that causes the muscle wasting...
30 April 2007 - by Heidi Nicholl 
A new drug is being trialled in humans which has been able to cure Duchenne muscular dystrophy (DMD) in mice with symptoms of the disease. The drug, named PTC124, has been developed by scientists working at the University of Massachusetts Medical School and Pennsylvania University Medical School...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.